Incremental benefits of novel pharmaceuticals in the United Kingdom 69 4♣ greatly across disease areas and compounds. Several novel drugs do not provide additional QALY gains over available therapies, but if offered at a lower price could still be of interest from a public cost-saving perspective even if not from the patient’s perspective. Providing transparent information on the added value of novel therapies enables patients and physicians to have reasonable expectations about the average net benefits of therapies at their disposal. Objectively evaluating the benefits contributed by novel pharmaceuticals provides insight not only into whether a given drug is worth its price once approved, but also into the therapeutic return on investment reaped by society from the substantial public and private sums expended on research and development. Finally, these figures provide a benchmark for future innovations.
RkJQdWJsaXNoZXIy MTk4NDMw